Gamma Glutamyl Transferase

GGT testing is covered to evaluate known or suspected hepatobiliary disease and related conditions, including alcohol- or drug-related injury, hepatotoxin exposure, medication-related hepatotoxicity per manufacturer guidance, infections, malignancy, post-liver transplantation status, disorders with liver involvement, and to differentiate the source of elevated alkaline phosphatase. Repeats are generally unnecessary after a normal result for stable non-hepatobiliary conditions and, when used to clarify the source of other abnormal enzymes, should generally be limited to once per week; GGT is also generally not useful for routine monitoring of established liver disease. Documentation should include the clinical indication and adherence to drug manufacturer testing recommendations, and billing should follow the quarterly Covered Code Lists.

"GGT testing is covered to provide information about known or suspected hepatobiliary disease."